534 related articles for article (PubMed ID: 18414108)
1. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
3. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
Lewis RA; Katz GJ; Weiss MJ; Landry TA; Dickerson JE; James JE; Hua SY; Sullivan EK; Montgomery DB; Wells DT; Bergamini MV;
J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
[TBL] [Abstract][Full Text] [Related]
6. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
7. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
[TBL] [Abstract][Full Text] [Related]
9. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
[TBL] [Abstract][Full Text] [Related]
10. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD
Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
[TBL] [Abstract][Full Text] [Related]
11. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
[TBL] [Abstract][Full Text] [Related]
12. The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.
Yildirim N; Sahin A; Gultekin S
J Glaucoma; 2008; 17(1):36-9. PubMed ID: 18303382
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
14. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
[TBL] [Abstract][Full Text] [Related]
15. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
Toris CB; Zhan G; Fan S; Dickerson JE; Landry TA; Bergamini MV; Camras CB
J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
[TBL] [Abstract][Full Text] [Related]
16. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
[TBL] [Abstract][Full Text] [Related]
17. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
18. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
DuBiner HB; Hubatsch DA
BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%.
Feldman RM; Tanna AP; Gross RL; Chuang AZ; Baker L; Reynolds A; Prager TC;
Ophthalmology; 2007 Jul; 114(7):1248-54. PubMed ID: 17509688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
